Latest William K. Oh Stories
-- Peak US urology organisation CUSP Group, LLC to evaluate MiStat(TM) technology SYDNEY, April 8, 2014 /PRNewswire/ -- Private Australian biotechnology company Minomic International
BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 11, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc.
Multiple Studies of Decipher Prostate Cancer Classifier Presented at 2014 ASCO Genitourinary Symposium SAN DIEGO, Jan.
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy.